Does Tocagen (TOCA) Look Attractive Now? B. Riley FBR Initiates Coverage

May 16, 2018 - By Richard Conner

Why Has B. Riley FBR Given Tocagen (TOCA) a $15 Price Target

EU: Tocagen (TOCA) coverage was started with a key ‘”Buy”‘ rating as well as a $15 target price per share at B. Riley FBR. The target by B. Riley FBR indicates upside of 53.85 % from the last stock close.

The stock increased 3.17% or $0.3 during the last trading session, reaching $9.75. About 141,469 shares traded or 24.89% up from the average. Tocagen Inc. (TOCA) has 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Tocagen Inc. (NASDAQ:TOCA) to report earnings on August, 8. They expect $-0.39 earnings per share, up 30.36 % or $0.17 from last year’s $-0.56 per share. After $-0.65 actual earnings per share reported by Tocagen Inc. for the previous quarter, Wall Street now forecasts -40.00 % EPS growth.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. The company has market cap of $194.14 million. The Company’s cancer-selective gene therapy platform is built on retroviral replicating vectors , which are designed to deliver therapeutic genes into the DNA of cancer cells. It currently has negative earnings. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma.

More notable recent Tocagen Inc. (NASDAQ:TOCA) news were published by: Prnewswire.com which released: “Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The …” on May 14, 2018, also Prnewswire.com with their article: “Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific Conferences” published on April 17, 2018, Benzinga.com published: “The Week Ahead In Biotech: PDUFA Dates, IPOs And More” on April 20, 2018. More interesting news about Tocagen Inc. (NASDAQ:TOCA) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For May 16, 2018” published on May 16, 2018 as well as Prnewswire.com‘s news article titled: “Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater …” with publication date: April 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.